A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.

Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J, Zhou Q, Chen W. · 2020

Read A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. by Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J, Zhou Q, Chen W. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7319273.txt.

Introduction

Chi and co-authors find a human antibody that neutralizes SARS-CoV-2 by striking a part of the spike most researchers had overlooked. Their study appeared in Science. Antibody hunting had concentrated on the spike's receptor binding domain, the part that grabs human cells. Screening antibodies from 10 convalescent patients, the team found a potent neutralizer that binds somewhere else entirely.

Cryo-electron microscopy located its target: the N-terminal domain, at the other end of the spike's head unit. An antibody attacking there works by a different route than receptor blockers. Pairing it with receptor-binding antibodies in a therapeutic cocktail could make treatment stronger and harder for the virus to escape, since it would need to change two separate sites at once.

Catalog record

CREATORChi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J, Zhou Q, Chen W.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE42 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7319273

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 By Xiangyang Chi, Renhong Yan, Jun Zhang, Guanying Zhang, Yuanyuan Zhang, Meng Hao, Zhe Zhang, Pengfei Fan, Yunzhu Dong, Yilong Yang, Zhengshan Chen, Yingying Guo Published in: Science (New York, N.y.) DOI: 10.1126/science.abc6952 ABSTRACT Hitting SARS-CoV-2 in a new spot A key target for therapeutic antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the spike protein, a trimeric protein complex with each monomer comprising an S1 and an S2 domain that mediate binding to host cells and membrane fusion, respectively. In addition to the receptor binding domain (RBD), S1 has an N-terminal domain (NTD). In searching for neutralizing antibodies, there has been a focus on the RBD. Chi et al. isolated antibodies from 10 convalescent patients and identified an antibody that potently neutralizes the virus but does not bind the RBD. Cryo–electron microscopy revealed the epitope as the NTD. This NTD-targeting antibody may be useful to combine with RBD-targeting antibodies in therapeutic cocktails. Science, this issue p. 650 The global outbreak of COVID-19 has emerged as a severe threat to human health (1–3). COVID-19 is caused by a novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is an enveloped, positive-strand RNA virus that causes symptoms such as cough, headache, dyspnea, myalgia, fever, and severe pneumonia in humans (1, 3–5). SARS-CoV-2 is a member of the β coronavirus genus, which also contains SARS-CoV and MERS-CoV, which caused epidemics in 2002 and 2012, respectively (6, 7). SARS-CoV-2 shares about 80% sequence identity to SARS-CoV and uses the same cellular receptor, angiotensin-converting enzyme 2 (ACE2) (8–16). The trimeric S protein decorates the surface of coronavirus and plays a pivotal role during viral entry (17, 18). During infection, the S protein is cleaved into the N-terminal S1 subunit and C-terminal S2 subunit by host proteases such as TMPRSS2 (18, 19) and changes conformation from the prefusion to the postfusion state (20). S1 and S2 comprise the extracellular domain (ECD; 1 to 1208 amino acids) and a single transmembrane helix and mediate receptor binding and membrane fusion, respectively (16). S1, which consists of the N-terminal domain (NTD) and the receptor binding domain (RBD), is critical in determining tissue tropism and host ranges (21, 22). The RBD is responsible for binding to ACE2, whereas the function of NTD is not well understood. In some coronaviruses, the NTD may recognize specific sugar moieties upon initial attachment and might play an important role in the prefusion-to-postfusion transition of the S protein (23–26). The NTD of the MERS-CoV S protein can serve as a critical epitope for neutralizing antibodies (26). The SARS-CoV-2 S protein–targeting monoclonal antibodies (mAbs) with potent neutralizing activity are a focus in the development of therapeutic interventions for COVID-19 (27–29). Many studies reported the functions and structures of SARS-CoV-2–neutralizing antibodies that target the RBD and inhibit the association between the S protein and ACE2 (28–34). The RBD-targeting antibodies, applied individually, might induce resistance mutations in the virus (26). Antibodies that target non-RBD epitopes might be added to antibody cocktail therapeutics for SARS-CoV-2. We thus sought to identify antibodies to different regions of the S protein and to the Nucleocapsid (N) protein. RESULTS Isolation of human mAbs from memory B cells and plasma B cells To isolate mAbs and analyze the humoral antibody responses to SARS-CoV-2, we collected plasma and peripheral blood mononuclear cells (PBMCs) from 10 Chinese patients who had recovered from SARS-CoV-2 infection. The age of donors ranges from 25 to 53 years. The interval from disease confirmation date to blood collection date ranged from 23 to 29 days for patients 1 to 5 and 10 to 15 days for patients 6 to 10 (table S1). We evaluated the titers of binding antibodies in plasma to different fragments of the SARS-CoV-2 S protein—including the full ECD, S1, S2, and the RBD—and to the N protein. Plasma from all the patients except donor 2 bound to all five SARS-CoV-2 protein segments, whereas that from donor 2 recognized S-ECD and S2 only (Fig. 1A). The neutralizing capacities of plasma against authentic SARS-CoV-2 and HIV-vectored pseudotyped SARS-CoV-2 are correlated [correlation coefficient (r) = 0.6868, P < 0.05] (Fig. 1B). These results indicate that humoral immune responses were specifically elicited for all 10 patients during their natural infection with SARS-CoV-2. [Figure: Isolation of antigen-specific mAbs from convalescent patients of SARS-CoV-2.(A) Reactions of plasma to SARS-CoV-2 proteins. S-ECD (extracellular domain of S protein), S1, S2, RBD (receptor binding domain), and N protein were used in ELISA to test the binding of plasma. Plasma of heathy donors were used as control, and cut-off values were calculated as optical density (OD) 450 of control × 2.1. Data were shown with mean and SD of a representative experiment. (B) The correlations between the authentic SARS-CoV-2 neutralizing antibody (NAb) titers and the pseudotyped SARS-CoV-2 NAb titers in plasma. Neutralizing assays of plasma against authentic SARS-CoV-2 were performed by using Vero E6 cells, and neutralization against pseudotyped SARS-CoV-2 were determined by using ACE2-293T cells. The correlations were calculated by means of Pearson correlation test in Graphpad 7.0. (C) Flow cytometry sorting from PBMCs of 10 convalescent patients. (D) Distribution of V gene families in heavy and light chains of all distinct clones (the total number is shown in the center of the pie charts) for each donor. (E) The number of amino acid (AA) and total nucleotide (Nt) mutations from the germline of all clonal sequences identified in (D) is shown. (F) CDR3 amino acid lengths of VH and VL of all clonal sequences identified in (D).] To isolate S protein–specific mAbs, we first sorted the immunoglobulin G–positive (IgG+) memory B cells from PBMCs of convalescent patients 1 to 5 with flow cytometry, using S-ECD as the probe (Fig. 1C). The percentage of S-ECD–reactive IgG+ B cells ranges from 0.56 to 11%, as revealed with fluorescence activating cell sorting (FACS). To avoid losing B cells with low copies of S-ECD–specific receptors on cell surfaces, we sorted plasma B cells from mixed PBMCs derived from another five convalescent patients (patients 6 to 10) without using S-ECD protein as the probe in flow cytometry. The percentage of plasma B cells in CD3-CD19+ B cells was 12.8%, which is higher than the percentage of memory B cells in CD3-CD19+ B cells (Fig. 1C). From the sorted B cells, we identified 9, 286, 43, 12, and 26 clones of single B cell from patients 1 to 5, respectively, and 23 clones of single B cell from the mixed PBMCs of patients 6 to 10 (Fig. 1D). The distribution of the sequenced heavy (IgH) gene families was comparable among the 10 donors, with VH3 being the most commonly used VH gene, whereas different donors displayed variable preferences for the light chain (IgL) gene families (Fig. 1D). The combination of V3 and J4, V3 and D3, and D3 and J4 were the most common usage for the IgH gene family (fig. S1). The average mutations of amino acids per mAb from memory B cells ranged from 17.50 to 48.04 for donors 1 to 5, respectively, whereas mAbs from plasma B cells possessed an average of 13.99 amino acid mutations for donors

Read the complete text